MADD (MAP kinase-activating death domain protein) is located on human chromosome 11p11 and it consists of 36 exons. It is also called as DENN or Rab3GEP. The IG20 (insulinoma glucagonoma clone 20) gene codes for MADD.
Synonyms: Anti-Denn; Anti-Kiaa0358; Anti-Map-kinase activating death domain; Anti-Rab3gep
MDL Number: MFCD01864859
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: MADD (MAP kinase-activating death domain protein) prevents apoptosis and induces human lung adenocarcinoma. It has the ability to bind to the death domain of TNFR1 (tumor necrosis factor receptor 1). MADD can activate TNF-a gene expression and also has the capability to promote the JNK (c-Jun NH2-terminal kinase) pathway. It modulates the recycling of Rab3 small G proteins and plays a major role in Ca2+-dependent neurotransmitter release and exocytosis. This protein also participates in inhibiting the apoptosis of neuronal cells.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC